Last reviewed 2026-06-02 · How we verify

PF-07321332 Dose 3 (pf-07321332-dose-3)

Pfizer Inc. · Phase 1 active ✓ Verified Jun 2026 Quality 15/100

PF-07321332 Dose 3 (generic name: pf-07321332-dose-3) is a drug developed by Pfizer Inc.. It is currently in Phase 1 development.

PF-07321332, also known as nirmatrelvir, is a medication being studied for its relative bioavailability and effect of food on bioavailability in healthy participants and those with COVID-19. It is administered in combination with ritonavir as part of the Nirmatrelvir/Ritonavir intervention.

Likelihood of approval

12.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Big-pharma sponsor +3.0pp
Pfizer Inc. is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	pf-07321332-dose-3
Sponsor	Pfizer Inc.
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

Dizziness
Presyncope
Abdominal distension
Diarrhoea
Puncture site pain
Blood thyroid stimulating hormone increased
SARS-CoV-2 test positive
Dysgeusia
Headache
Tremor
Balance disorder
Hypertonia

Key clinical trials

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PF-07321332 Dose 3 CI brief — competitive landscape report
PF-07321332 Dose 3 updates RSS · CI watch RSS
Pfizer Inc. portfolio CI

Frequently asked questions about PF-07321332 Dose 3

What is PF-07321332 Dose 3?

PF-07321332 Dose 3 (pf-07321332-dose-3) is a pharmaceutical drug developed by Pfizer Inc..

Who makes PF-07321332 Dose 3?

PF-07321332 Dose 3 is developed by Pfizer Inc. (see full Pfizer Inc. pipeline at /company/pfizer).

What is the generic name of PF-07321332 Dose 3?

pf-07321332-dose-3 is the generic (nonproprietary) name of PF-07321332 Dose 3.

What development phase is PF-07321332 Dose 3 in?

PF-07321332 Dose 3 is in Phase 1.

What are the side effects of PF-07321332 Dose 3?

Common side effects of PF-07321332 Dose 3 include Dizziness, Presyncope, Abdominal distension, Diarrhoea, Puncture site pain, Blood thyroid stimulating hormone increased.

Manufacturer: Pfizer Inc. — full pipeline

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing